This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suardet, L. Articles by Odartchenko, N. Search for Related Content PubMed PubMed Citation Articles by Suardet, L. Articles by Odartchenko, N.

Responsiveness of Three Newly Established Human Colorectal Cancer Cell Lines to Transforming Growth Factors ß₁ and ß₂¹

Swiss Institute for Experimental Cancer Research, CH-1066 Epalinges sur Lausanne [L. S., B. S., N. O.], and Division Autonome de Génétique Médicale [A-C. G.] and Chirurgie Générale [J-M. C., J-C. G.], Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland; and Department of Oncology and Immunology, Nippon Roche Research Center, Kamakura, Japan [J. F. E.]

We have established 3 new human colorectal cancer cell lines (LS411N, LS513, and LS1034) from clinical biopsy samples. These lines are tumorigenic and grow s.c. as adenocarcinomas in nude mouse xenografts. Specific marker chromosomes are observed in each line. Carcinoembryonic antigen is expressed at the surface of all 3 lines, but with marked quantitative differences. Indeed, less than 10% of the cells from the HT-29 line used as a reference express carcinoembryonic antigen while more than 90% of the LS1034 cells do so. LS513 and LS1034 consistently express HLA class I antigens and intercellular adhesion molecule 1 which are not detected at the surface of the LS411N cells. No expression of HLA class II antigens DR, DQ, and DP has been measured on any of the lines. All three lines grow well in 5% fetal calf serum medium without addition of exogenous growth factors. The LS1034 line has been adapted to growth in serum-free conditions and exhibits increased clonogenicity when cells are seeded in serum-free methylcellulose medium, as compared with medium containing 5% fetal calf serum. The LS513 and LS1034 lines have proved to be of particular interest since they respond to the growth-inhibitory action of TGF-ß₁ and TGF-ß₂ in both liquid and semisolid medium. Both factors were, at pM concentrations, equipotent inhibitors of LS1034 cell proliferation. In contrast, higher concentrations of TGF-ß₁ are inhibitory for proliferation of LS513 cells, whereas TGF-ß₂ has no effect on the growth of these cells in liquid assay. On this basis, using appropriate anti-TGF-ß₁ and anti-TGF-ß₁ IgY, we developed a bioassay for TGF-ß₁ and TGF-ß₂. Two of the three lines have indeed been shown to produce latent-TGF-ß₁ activity.

¹ This work was supported by grants from the Swiss National Science Foundation, the Swiss League Against Cancer, the Foundation Hoffmann-La Roche, and the Fonds de Recherche sur les Lymphomes Malins.

² To whom requests for reprints should be addressed.

Received 11/ 4/91. Accepted 4/20/92.

This article has been cited by other articles:

				M. Steinert, M. Wobus, C. Boltze, A. Schutz, M. Wahlbuhl, J. Hamann, and G. Aust Expression and Regulation of CD97 in Colorectal Carcinoma Cell Lines and Tumor Tissues Am. J. Pathol., November 1, 2002; 161(5): 1657 - 1667. [Abstract] [Full Text] [PDF]

				M. E. Harris-White, T. Chu, Z. Balverde, J. J. Sigel, K. C. Flanders, and S. A. Frautschy Effects of Transforming Growth Factor-beta (Isoforms 1-3) on Amyloid-beta Deposition, Inflammation, and Cell Targeting in Organotypic Hippocampal Slice Cultures J. Neurosci., December 15, 1998; 18(24): 10366 - 10374. [Abstract] [Full Text] [PDF]

				S. Zhou, P. Buckhaults, L. Zawel, F. Bunz, G. Riggins, J. Le Dai, S. E. Kern, K. W. Kinzler, and B. Vogelstein Targeted deletion of Smad4 shows it is required for transforming growth factor beta  and activin signaling in colorectal cancer cells PNAS, March 3, 1998; 95(5): 2412 - 2416. [Abstract] [Full Text] [PDF]

				S. W. Qian, J. K. Burmester, M. L.-S. Tsang, J. A. Weatherbee, A. P. Hinck, D. J. Ohlsen, M. B. Sporn, and A. B. Roberts Binding Affinity of Transforming Growth Factor-beta for Its Type II Receptor Is Determined by the C-terminal Region of the Molecule J. Biol. Chem., November 29, 1996; 271(48): 30656 - 30662. [Abstract] [Full Text] [PDF]

				W Cui, D J Fowlis, F M Cousins, E Duffie, S Bryson, A Balmain, and R J Akhurst Concerted action of TGF-beta 1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes & Dev., April 15, 1995; 9(8): 945 - 955. [Abstract] [PDF]

				C.-Y. Li, L. Suardet, and J. B. Little Potential Role of WAF1/Cip1/p21 as a Mediator of TGF-beta Cytoinhibitory Effect J. Biol. Chem., March 10, 1995; 270(10): 4971 - 4974. [Abstract] [Full Text] [PDF]

				S. Kirkland and K Henderson Endocrine and mucous differentiation by a cloned human rectal adenocarcinoma cell line (HRA-19) in vitro: inhibition by TGF-beta 1 J. Cell Sci., January 4, 1994; 107(4): 1041 - 1046. [Abstract] [PDF]